Latest Conference Articles

AmerisourceBergen/Xcenda Policy Experts Discuss Biosimilar Strategy

October 31 2021

Two AmerisourceBergen/Xcenda policy experts discuss the coming wave of pharmacy benefit biosimilars, formulary decisions, pricing transparency, and the Biden Administration’s push for lower-cost biologics.

An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming

Tony Hagen

October 27 2021

Competitors in the field of adalimumab and insulin products may soon include “authorized biologics” in addition to biosimilars and interchangeable biosimilars, a pharmacy expert explains at the Academy of Managed Care Pharmacy Nexus 2021 meeting.

Survey: Moderate Acceptance of Anti-TNF Biosimilars Among Patients With Immune-Mediated Conditions

Tony Hagen

October 24 2021

Patients with and without experience with tumor necrosis factor (TNF)–blocker biologics have incomplete knowledge of biosimilars for these agents, according to findings presented at the Academy of Managed Care Pharmacy 2021 Nexus meeting.

Survey: US Pharmacists Have Homework to Do on Biosimilar Interchangeability

Tony Hagen

October 23 2021

Pharmacists need to brush up on their knowledge of the interchangeable biosimilar designation, investigators said in a survey presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting.

Amgen Executive Discusses Prominent Biosimilar Trends

October 21 2021

In this interview with The Center for Biosimilars®, Amgen biosimilars expert Jen Norton discusses regulatory and policy incentives, interchangeable biosimilars, and market share gains.

Coherus BioSciences Reaches Clinical and Regulatory Milestones for Udenyca and CHS-201

Tony Hagen

October 6 2021

Positive findings for Coherus BioSciences' ranibizumab candidate (CHS-201) were presented at the Scientific Meeting of the Retina Society, and the company said equivalence end points were met for an on-body injector version of Udenyca (pegfilgrastim).

Remsima Delivers Positive Results in IBD Switching Study

Tony Hagen

October 4 2021

Studies of the infliximab biosimilar Remsima in patients with inflammatory bowel disease were presented at United European Gastroenterology Week 2021.

Tanvex Presents Positive Findings for Trastuzumab Candidate at ESMO

Tony Hagen

September 20 2021

Investigators said TX05 met pathologic complete response criteria for equivalence to the originator product, Herceptin. The biosimilar candidate also fell within objective response rate, immunogenicity, safety, and tolerability margins for similarity.

Biocad's BCD-021 Bevacizumab Biosimilar Demonstrates Equivalence in NSCLC

Tony Hagen

September 17 2021

BCD-021 demonstrated equivalence in a phase 3 study involving Russian and Indian patients with advanced non–small cell lung cancer (NSCLC).

MIL60 Bevacizumab Biosimilar Candidate Demonstrates Equivalence in NSCLC

Tony Hagen

September 16 2021

MIL60 bevacizumab biosimilar candidate demonstrates equivalence to the originator Avastin in a population of Chinese patients with non–small cell lung cancer (NSCLC) treated in a frontline setting.